Iovance Biotherapeutics (NASDAQ: IOVA) aims to improve patient care for people living with cancer. Iovance is investigating T cell-based therapies, known as tumor infiltrating lymphocytes (TIL), which use a patient’s own immune cells to attack cancer. 

Biotechnology

Iovance Biotherapeutics

Frederick G. Vogt

Joseph Yglesias

Sean Rocca

Kerry Elizabeth Wilson Esq.

Asq Cqa Ulises Villavicencio

Stefanie Bulilan

Renee Doggett

Mariam Mirgoli

Nicholas Rojeski

Jessica Reckner

Ahmed Tawashi

Hequn Yin

Kevin Smyth

Howard B. Johnson

Jean-Marc Bellemin

Friedrich Graf Finckenstein

Tracy Winton

Brian Shew

Igor Bilinsky

Leadership Team

Clinical Operations and Research

Quality Assurance and Compliance

Information Technology and Data Management

Finance and Accounting

Human Resources and Talent Acquisition

Teams at Iovance Biotherapeutics